OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis $2.55 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.55▼$2.5550-Day Range$2.25▼$2.8852-Week Range$1.40▼$7.65VolumeN/AAverage Volume2,767 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Idorsia alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Idorsia Stock (OTCMKTS:IDRSF)Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.Read More IDRSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDRSF Stock News HeadlinesJuly 25 at 8:48 AM | finanznachrichten.deIdorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first half 2024July 25 at 8:48 AM | finance.yahoo.comIdorsia Ltd (VTX:IDIA) most popular amongst individual investors who own 38%, insiders hold 32%July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 20, 2024 | finanznachrichten.deIdorsia Pharmaceuticals Ltd: Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference callJuly 18, 2024 | globenewswire.comInvitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference callJuly 1, 2024 | globenewswire.comIdorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertensionJune 21, 2024 | globenewswire.comIdorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' categoryJune 13, 2024 | globenewswire.comIdorsia holds its Annual General Meeting of ShareholdersJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 24, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF)May 23, 2024 | globenewswire.comIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersMay 21, 2024 | globenewswire.comIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsMay 21, 2024 | globenewswire.comIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueMay 14, 2024 | globenewswire.comInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callMay 1, 2024 | globenewswire.comIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondApril 27, 2024 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 26, 2024 | finance.yahoo.comJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionApril 23, 2024 | globenewswire.comIdorsia publishes an invitation to a bondholder meetingSee More Headlines Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CUSIPN/A CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jean-Paul Clozel M.D. (Age 69)CEO & Executive Director Comp: $1.5MMr. André C. Muller (Age 61)Executive VP & CFO Dr. Martine Clozel (Age 69)Executive VP & Chief Scientific Officer Mr. Andrew C. Weiss (Age 56)Senior VP and Head of Investor Relations & Corporate Communications Mr. Julien Gander L.L.M. (Age 45)Senior VP, Group General Counsel & Company Secretary Mr. Alexander Khatuntsev (Age 46)Senior VP & Head of Global Human Resources Dr. Guy Braunstein M.D. (Age 68)Executive VP & Chief Medical Officer Mr. Olivier Lambert (Age 58)Senior VP & Head of Technical Operations Mr. Markus A. Riederer (Age 62)Senior VP & Head of Drug Discovery Biology Mr. Christoph Boss (Age 56)Senior VP & Head of Drug Discovery Chemistry More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IDRSF Stock Analysis - Frequently Asked Questions How have IDRSF shares performed this year? Idorsia's stock was trading at $2.45 on January 1st, 2024. Since then, IDRSF shares have increased by 4.1% and is now trading at $2.55. View the best growth stocks for 2024 here. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IDRSF) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
